Our Clinical Sites and Trials

A5415: A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV

The purpose of this study is to see if cenicriviroc mesylate (or CVC) can reduce inflammation of the arteries (the…

Open and enrolling

24 weeks

See locations

A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH)

This four-step study compares Long-Acting (LA) Injectable Antiretroviral Therapy (ART) to standard of care (SOC) oral ART in previously non-adherent…

Open and enrolling

Steps 1-3 combined are a total of 128 weeks. Step 4 lasts 52 weeks.

See locations

A5128: US Genomic Sampling

Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…

Open and enrolling

See locations

A5243: Non-US Genomic Sampling

Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…

Open and enrolling

See locations

A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)

Weight gain after starting HIV therapy is common, but recent studies have found that some people with HIV (PWH) who…

Open and enrolling

Participants will be on study treatment for 48 weeks.

See locations

A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function

Since the early days of the HIV epidemic cytomegalovirus (CMV) has been one of the most common and devastating opportunistic…

Open and enrolling

About 2 years (96 weeks).

See locations